IDEAYA Biosciences Inc (NASDAQ: IDYA), a California-based precision medicine oncology company, announced on Sunday that it has entered an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program, with Jiangsu Hengrui Pharmaceuticals Co, Ltd (Hengrui Pharma, SHA: 600276), a global pharmaceutical company headquartered in China.
Under the terms of the contract, IDEAYA is to develop and commercialise SHR-4849 globally outside of Greater China.
SHR-4849 is claimed to have indicated promising antitumor activity in preclinical studies, which includes tumour regression as a monotherapy in multiple models. Presently, the product is being assessed in a phase one clinical trial for advanced solid tumours in China (NCT06443489).
Jiangsu is aiming to file a US IND for SHR-4849 in the first half of 2025.
Kazia Therapeutics updates on paxalisib regulatory pathway after FDA meeting
Veru sells FC2 Female Condom business, focuses on enobosarm
FDA approve Opdivo Qvantig with ENHANZE for subcutaneous use
CARsgen Therapeutics reveals positive CT041-ST-01 (NCT04581473) Phase II clinical trial results
Duality Biologics reveals B7H4 ADC milestone achievement and license exercise by BeiGene
Precigen submits BLA for PRGN-2012 for treatment of recurrent respiratory papillomatosis
Novartis Phase III study of intrathecal onasemnogene abeparvovec meets primary endpoint in SMA
Hemogenyx Pharmaceuticals announces first clinical site for HG-CT-1 Phase I trial
Ondine Biomedical enrolls first patient in US Phase 3 trial
IDEAYA Biosciences enters license agreement with Jiangsu Hengrui Pharmaceuticals
Huadong Medicine collaborates with SynerK
Microtech commences human clinical trial of microsensor platform for heart failure
Ractigen Therapeutics doses first patient in Phase I clinical trial of RAG-17